A Simats1, T García-Berrocoso1, A Penalba1, D Giralt1, G Llovera2, Y Jiang3, L Ramiro1, A Bustamante1, E Martinez-Saez4, F Canals5, X Wang5, A Liesz2, A Rosell1, J Montaner1. 1. Neurovascular Research Laboratory, Vall d'Hebron Institute of Research (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain. 2. Institute for Stroke and Dementia Research, Klinikum de Universität München, Munich, Germany. 3. Neuroprotection Research Laboratory, Departments of Neurology and Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA. 4. Neuropathology Unit, Department of Pathology, Vall d'Hebron Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain. 5. Proteomics Laboratory, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
Abstract
BACKGROUND: CCL23 role in the inflammatory response after acute brain injuries remains elusive. Here, we evaluated whether CCL23 blood levels associate with acquired cerebral lesions and determined CCL23 predictive capacity for assessing stroke prognosis. We used preclinical models to study the CCL23 homologous chemokines in rodents, CCL9 and CCL6. METHODS: Baseline CCL23 blood levels were determined on 245 individuals, including ischaemic strokes (IS), stroke mimics and controls. Temporal profile of circulating CCL23 was explored from baseline to 24 h in 20 of the IS. In an independent cohort of 120 IS with a 3-month follow-up, CCL23 blood levels were included in logistic regression models to predict IS outcome. CCL9/CCL6 cerebral expression was evaluated in rodent models of brain damage. Both chemokines were also profiled in circulation and histologically located on brain following ischaemia. RESULTS: Baseline CCL23 blood levels did not discriminate IS, but permitted an accurate discrimination of patients presenting acute brain lesions (P = 0.003). IS exhibited a continuous increase from baseline to 24 h in circulating CCL23 (P < 0.001). Baseline CCL23 blood levels resulted an independent predictor of IS outcome at hospital discharge (ORadj : 19.702 [1.815-213.918], P = 0.014) and mortality after 3 months (ORadj : 21.47 [3.434-134.221], P = 0.001). In preclinics, expression of rodent chemokines in neurons following cerebral lesions was elevated. CCL9 circulating levels decreased early after ischaemia (P < 0.001), whereas CCL6 did not alter within the first 24 h after ischaemia. CONCLUSIONS: Although preclinical models do not seem suitable to characterize CCL23, it might be a novel promising biomarker for the early diagnosis of cerebral lesions and might facilitate the prediction of stroke patient outcome.
BACKGROUND:CCL23 role in the inflammatory response after acute brain injuries remains elusive. Here, we evaluated whether CCL23 blood levels associate with acquired cerebral lesions and determined CCL23 predictive capacity for assessing stroke prognosis. We used preclinical models to study the CCL23 homologous chemokines in rodents, CCL9 and CCL6. METHODS: Baseline CCL23 blood levels were determined on 245 individuals, including ischaemic strokes (IS), stroke mimics and controls. Temporal profile of circulating CCL23 was explored from baseline to 24 h in 20 of the IS. In an independent cohort of 120 IS with a 3-month follow-up, CCL23 blood levels were included in logistic regression models to predict IS outcome. CCL9/CCL6 cerebral expression was evaluated in rodent models of brain damage. Both chemokines were also profiled in circulation and histologically located on brain following ischaemia. RESULTS: Baseline CCL23 blood levels did not discriminate IS, but permitted an accurate discrimination of patients presenting acute brain lesions (P = 0.003). IS exhibited a continuous increase from baseline to 24 h in circulating CCL23 (P < 0.001). Baseline CCL23 blood levels resulted an independent predictor of IS outcome at hospital discharge (ORadj : 19.702 [1.815-213.918], P = 0.014) and mortality after 3 months (ORadj : 21.47 [3.434-134.221], P = 0.001). In preclinics, expression of rodent chemokines in neurons following cerebral lesions was elevated. CCL9 circulating levels decreased early after ischaemia (P < 0.001), whereas CCL6 did not alter within the first 24 h after ischaemia. CONCLUSIONS: Although preclinical models do not seem suitable to characterize CCL23, it might be a novel promising biomarker for the early diagnosis of cerebral lesions and might facilitate the prediction of strokepatient outcome.
Authors: Katarzyna Pawlik; Anna Piotrowska; Klaudia Kwiatkowski; Katarzyna Ciapała; Katarzyna Popiolek-Barczyk; Wioletta Makuch; Joanna Mika Journal: Immunology Date: 2020-02-05 Impact factor: 7.397
Authors: Alba Simats; Laura Ramiro; Teresa García-Berrocoso; Ferran Briansó; Ricardo Gonzalo; Luna Martín; Anna Sabé; Natalia Gill; Anna Penalba; Nuria Colomé; Alex Sánchez; Francesc Canals; Alejandro Bustamante; Anna Rosell; Joan Montaner Journal: Mol Cell Proteomics Date: 2020-08-31 Impact factor: 5.911
Authors: Júlia Faura; Alejandro Bustamante; Anna Penalba; Dolors Giralt; Alba Simats; Elena Martínez-Sáez; Daniel Alcolea; Juan Fortea; Alberto Lleó; Charlotte E Teunissen; Wiesje M van der Flier; Laura Ibañez; Oscar Harari; Carlos Cruchaga; Mar Hernández-Guillamón; Pilar Delgado; Joan Montaner Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472
Authors: Philip Dyhrfort; Qiujin Shen; Fredrik Clausen; Måns Thulin; Per Enblad; Masood Kamali-Moghaddam; Anders Lewén; Lars Hillered Journal: J Neurotrauma Date: 2019-06-17 Impact factor: 5.269
Authors: Benton Maglinger; Jacqueline A Frank; Christopher J McLouth; Amanda L Trout; Jill Marie Roberts; Stephen Grupke; Jadwiga Turchan-Cholewo; Ann M Stowe; Justin F Fraser; Keith R Pennypacker Journal: J Neurointerv Surg Date: 2020-07-08 Impact factor: 5.836